December 5, 2019 -New FDA Approval Extends Label to Including the i:X’s® Detection of Bacteria and Digital Wound Measurement
TORONTO, Canada – (December 5, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of fluorescence in wounds, has received FDA 510(k) clearance for its i:X® handheld fluorescence imaging device
… Read MoreNovember 4, 2019 -Forthcoming Category lll CPT Code Reflects the Published Clinical Evidence and a Determination of Significant Value of Real-Time Fluorescence Imaging Across the Wound Care Treatment Pathway
TORONTO, Canada – (November 4, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of bacteria for chronic wounds, has
… Read MoreOctober 11, 2019 -
Multiple Trials Illustrate the Significant Clinical Benefit of MolecuLight’s Point-of-Care Fluorescence Imaging Device for Chronic Wound Management
LAS VEGAS, USA and TORONTO, Canada – (October 11, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of bacteria for chronic wounds and its i:X point-of-care fluorescence imaging
… Read MoreOctober 4, 2019 -
Point-of-Care Fluorescence Imaging for Chronic Wounds and its Significant Clinical Benefits are Featured at the Largest Canadian Wound Care Conference in 5 Clinical Talks and Posters
NIAGARA FALLS, Canada and TORONTO, Canada – (October 4, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization
… Read MoreAugust 19, 2019 -
TORONTO, Canada – (August 20, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of bacteria for chronic wounds, announced it has secured a $7.5 million USD term loan from Oxford Finance LLC, a specialty finance firm providing senior debt to life sciences and healthcare services
… Read MoreAugust 14, 2019 -
photonamic GmbH & Co. KG (Head office: Pinneberg, Germany; CEO: Ulrich Kosciessa, Ph.D.) (“photonamic”), a subsidiary of SBI Holdings, Inc. (Head office: Minato-ku,Tokyo; Representative Director, President and CEO: Yoshitaka Kitao) is engaged in the business of pharmaceutical development of 5-aminolevulinic acid (“5-ALA”) (*) hereby announces the acquisition of the
… Read MoreOctober 17, 2017 -
TORONTO, CANADA. MolecuLight, a global leader in fluorescence image-guidance solutions, is pleased to announce the appointment of industry veteran Anil Amlani as Chief Executive Officer effective September 29, 2017.
William Wignall, Chairman of the Board at MolecuLight, commented, “The Board is delighted to welcome Anil as MolecuLight’s new CEO. Anil
… Read MoreApril 5, 2017 -SAWC Spring in San Diego attracted over 2000 attendees and 200 exhibitors
This year’s SAWC Spring in San Diego attracted over 2000 attendees and 200 exhibitors. Amongst the many great presentations, Dr. Greg Schultz’s and Rosemary Hill’s particularly stood out. Dr Schultz (University of Florida, USA) presented in the Science
… Read MoreMarch 6, 2017 -Reliability in microbiology wound sampling
In the article ‘Improved detection of clinically relevant wound bacteria using autofluorescence image-guided sampling in diabetic foot ulcers’ recently published (March 2017) in International Wound Journal, Ottolino-Perry et al. present data from a clinical trial highlighting how the conventional Levine method of sampling may need to be reconsidered
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2025
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.